Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study

SIMPLE SUMMARY: We prospectively analyzed COVID-19 morbidity and severity in 200 consecutive patients with CLL. Increased COVID-19 morbidity was observed in vaccinated patients with CLL. With a median follow-up of 23.4 months, 41% of patients experienced COVID-19. Most patients, 36.5%, experienced C...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauro, Francesca R., Giannarelli, Diana, Galluzzo, Clementina M., Visentin, Andrea, Frustaci, Anna M., Sportoletti, Paolo, Vitale, Candida, Reda, Gianluigi, Gentile, Massimo, Levato, Luciano, Murru, Roberta, Armiento, Daniele, Molinari, Maria C., Proietti, Giulia, Pepe, Sara, De Falco, Filomena, Mattiello, Veronica, Barabino, Luca, Amici, Roberta, Coscia, Marta, Tedeschi, Alessandra, Girmenia, Corrado, Trentin, Livio, Baroncelli, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251854/
https://www.ncbi.nlm.nih.gov/pubmed/37296954
http://dx.doi.org/10.3390/cancers15112993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251854/
https://www.ncbi.nlm.nih.gov/pubmed/37296954
http://dx.doi.org/10.3390/cancers15112993

Ejemplares similares